Enter your search term below:
David Moolten, MD Medical Director American Red Cross United States Why the Quality and Make-up of Starting Material Matters The familiar truism garbage in, garbage out can be ruinously accurate in the setting of cell and gene therapy production. What is in the bag at the beginning...
Nathan Manley, PhD Senior Principal, Head of Nonclinical Dark Horse Consulting Group, Inc. United States Construction of an efficient, pressure-tested, development roadmap is an essential tool for preclinical cell and gene therapy (CGT) companies looking to obtain stakeholder buy-in and...
For drug sponsors, setting up your CGT product for regulatory viability and commercial success means investing the time and budget to empower process design, as well as on-time planning of process performance qualification (PPQ) and continued process verification (CPV) activities. Easier said...
Achieving consistent and effective outcomes in CAR T and other immune effector cell (IEC) therapies relies heavily on getting lymphodepletion “right.” Emerging evidence shows that both under- and over-exposure can impact safety, efficacy, and long-term persistence, making optimized dosing...
Dec 17, 2025 | 09:00 - 10:00 PT
Join us for a dynamic 60-minute webinar exploring how artificial intelligence (AI), data analytics and machine learning (ML) are transforming donor selection and starting material characterization for cell and gene therapy (CGT) manufacturing. Featuring experts in the industry, this session will...
Dec 09, 2025 | 08:00 - 09:00 PT
Nov 26, 2025 07:00 - May 09, 2026 16:00 PT
From October 27–31, 2025, ISCT celebrated the successful conclusion of our 2025 Cell Therapy Leadership Training Program. Since its launch in 2015, this course has been a flagship initiative, cultivating the next generation of cell and gene therapy leaders on a global scale. Alongside our 15...
Nov 19, 2025 07:00 - May 09, 2026 16:00 PT
The International Society for Cell & Gene Therapy (ISCT), Alliance for Regenerative Medicine (ARM), and American Society of Gene & Cell Therapy (ASGCT) reaffirm our collective position, as articulated in the Cytotherapy editorial “ International Call for a 10-Year Moratorium on...
The International Society for Cell & Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), and the American Society of Gene & Cell Therapy (ASGCT) reaffirm our collective position, as articulated in the Cytotherapy editorial “International Call for a 10-Year Moratorium on...